AKT1 and lung cancer: MK2206 also did not induce cell death in lung cancer cell lines with activating EGFR mutations (Figure 1—figure supplement 4, Figure 1—source data 1) which have been linked with aberrant PI3K pathway activation (Engelman et al., 2005), suggesting that the mode of PI3K activation is critical in establishing AKT addiction in cancer.